Biothera announced today that it has successfully completed a Phase I clinical trial for Imprime PGG, its investigational new drug for the treatment of various cancers and the enhancement of white blood cell mobilization and production.
The single-dose, dose-escalating Phase I study examined the safety and tolerability of a single injection of Imprime PGG in 24 healthy volunteers.
As anticipated based on previous research, Imprime PGG demonstrated a strong safety profile.
